Objective: Studies on gut microbiota and metabolic diseases are intensly growing, however very few of these data came from Indonesia. This study learns about the newly discovered bacteria Akkermansia muciniphila in the diabetic and non-diabetic Balinese population. Methods: We conducted an analytic cross-sectional study with participants from public health centers in Denpasar, Bali during the period of March-July 2017. Of 109 participants 16 were diabetic-no-treatment, 24 were on treatment, 23 were pre-diabetic and 46 were non-diabetic as diagnosed by general practitioners. Treatment groups were 33.3% on metformin and 66.7% on metformin-combined dual therapy. We determined demographic information, anthropometry, capillary blood glucose level and diabetes treatment. We collected each participant’s faecal material from which qPCR was conducted for A.muciniphila quantification. All groups were analysed for correlation and difference in each parameter. Results: Treatment group showed the highest number of A.muciniphila with mean log copy number (LCN) of 6.18/gram feces followed by pre-diabetic (5.61/gram feces), non-diabetic (5.31/gram feces) and diabetic-no-treatment group (5.28/gram feces) respectively. We found correlation between waist circumference and the amount of A.muciniphila in general r = -0.40 (p = 0.04), however no correlation found in each group. Further analysis showed diabetes treatment group had significantly higher proportion of A.muciniphila compared to diabetic-no-treatment group (p = 0.01) and interestingly, non-diabetic group (p = 0.02). Furthermore, difference test based on types of diabetes treatment proved no significant difference of A.muciniphila between those with metformin on single and combined therapy. Conclusion: Our results show the number of A.muciniphila is rather related with diabetes treatment than abdominal adiposity. This supports the idea of metformin as a potential gut modulator through enrichment of mucin-degrading bacteria. Our data showing better profile of A.muciniphila with diabetes therapy than non-diabetic group may suggest a strong clinical effect of metformin in diabetic patients. Its mechanism however, needs to be investigated further for developing novel diabetes therapy in the future.